1. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403–19.
2. Aelajado MC, Pisoni R, Dudenbostel T et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7–12.
3. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults.
4. Dudenbostel T, Calhoun D. Refractory Hypertension a novel phenotype of antihypertensive treatment failure. Hypertension 2016; 67: 1085–92.
5. Диагностика и лечение артериальной гипертонии (клинические рекомендации). Кардиологический вестник. 2015; Х (1). / Diagnostika i lechenie arterialnoj gipertonii (klinicheskie rekomendacii). Kardiologicheskij vestnik. 2015; Х (1). [in Russian]
6. Dudenbostel T, Acelajado MC, Pisoni R et al. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension 2015; 66: 126–33.
7. De la Sierra A et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57 (5): 898–902.
8. Muntner P et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64 (5): 1012–21.
9. Calhoun DA, Booth JN, Oparil S et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451–8.
10. Чазова И.Е., Данилов Н.М., Литвин А.Ю. Рефрактераня артериальная гипертония. Монография. М.: Атмосфера, 2014. / Chazova I.E., Danilov N.M., Litvin A.Yu. Refrakteranya arterialnaya gipertoniya. Monografiya. M.: Atmosfera, 2014. [in Russian]
11. Velasco A, Siddiqui M, Kreps E et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension 2018.
12. Irvin MR, Booth JN, Shimbo D et al. Calhoun/Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014; 8: 405–13.
13. Armario P, Oliveras A, Blanch P et al. Refractory hypertension: prevalence, associated factors and differences with resistant hypertension. J Hypertension 2017. DOI: 10.1097/01.hjh.0000523892.30290.dd
14. Modolo R, de Faria AP, Sabbatini AR et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens 2015; 9: 397–402.
15. Gaddam KK et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 (11): 1159–64.
16. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci 2017; 3 (9): e430.

________________________________________________

1. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51 (6): 1403–19.
2. Aelajado MC, Pisoni R, Dudenbostel T et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012; 14: 7–12.
3. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults.
4. Dudenbostel T, Calhoun D. Refractory Hypertension a novel phenotype of antihypertensive treatment failure. Hypertension 2016; 67: 1085–92.
5. Diagnostika i lechenie arterialnoj gipertonii (klinicheskie rekomendacii). Kardiologicheskij vestnik. 2015; Х (1). [in Russian]
6. Dudenbostel T, Acelajado MC, Pisoni R et al. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension 2015; 66: 126–33.
7. De la Sierra A et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011; 57 (5): 898–902.
8. Muntner P et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014; 64 (5): 1012–21.
9. Calhoun DA, Booth JN, Oparil S et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension 2014; 63: 451–8.
10. Chazova I.E., Danilov N.M., Litvin A.Yu. Refrakteranya arterialnaya gipertoniya. Monografiya. M.: Atmosfera, 2014. [in Russian]
11. Velasco A, Siddiqui M, Kreps E et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension 2018.
12. Irvin MR, Booth JN, Shimbo D et al. Calhoun/Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. J Am Soc Hypertens 2014; 8: 405–13.
13. Armario P, Oliveras A, Blanch P et al. Refractory hypertension: prevalence, associated factors and differences with resistant hypertension. J Hypertension 2017. DOI: 10.1097/01.hjh.0000523892.30290.dd
14. Modolo R, de Faria AP, Sabbatini AR et al. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens 2015; 9: 397–402.
15. Gaddam KK et al. Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med 2008; 168 (11): 1159–64.
16. Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci 2017; 3 (9): e430.

А.В.Аксенова*, Т.Е.Есаулова, О.А.Сивакова, И.Е.Чазова

ФГБУ «Национальный медицинский исследовательский центр кардиологии» Минздрава России. 121552, Россия, Москва, ул. 3-я Черепковская, д. 15А
*aksenovaannav@gmail.com

________________________________________________

A.V.Aksenova*, T.E.Esaulova, O.A.Sivakova, I.E.Chazova

National Medical Research Center of Cardiologyof the Ministry of Health of the Russian Federation. 121552, Russian Federation, Moscow, ul. 3-ia Cherepkovskaia, d. 15a
*aksenovaannav@gmail.com